Almac’s Radiolabeling services: enhancing drug development efficiency and regulatory compliance
Almac provides a streamlined approach for pharma companies to meet the Radiolabeling requirements of Phase 1 to 3 clinical trials, signaling our intent to meet the high-quality service needs of the sector. Our capability to provide cGMP services for final drug candidates, peptides, small molecules, and advanced intermediates effectively answers the demands of the market.
Read our latest Almac Voice from Dr. Sean Kitson, Investigator of Radiochemistry, to find out more on Almac’s Radiolabeling and stable isotope labeling services for pharmaceutical companies and CROs.
